Newswise — LOS ANGELES— Patients who’ve suffered from traumatic brain injuries (TBIs) have changes in tiny blood vessels in their brains that researchers believe are linked to a range of cognitive symptoms, according to new findings presented at the 2018 American Academy of Neurology (AAN) Annual Meeting. The findings may help doctors pinpoint specific types of TBIs and tailor personalized therapies.

The study was led by Ramon Diaz-Arrastia, MD, PhD, director of the Traumatic Brain Injury Clinical Research Center at the Perelman School of Medicine at University of Pennsylvania, and presented by Sarah Woodson, MD, a neurology resident at Walter Reed National Military Medical Center (Abstract #S49.001).  

"The relationship between microvascular and structural injury in chronic TBI has been recognized for years, but underappreciated," Diaz-Arrastia said. "This research adds another layer to our understanding of TBI and ways to better treat patients, who in some cases have had TBI symptoms for years."

The research examined whether microvascular injury had a role in some of the cognitive and psychological problems that are common in TBI patients by assessing the correlation between blood flow and cerebral reactivity—a change in blood flow in the brain in response to a stimulus—in TBI patients. Using functional MRI-Blood-Oxygen Level dependent (BOLD) and Diffusion Tensor Imaging (DTI)—which together makes it possible to see inside the brain in great detail—the team assessed the strength and function of small blood vessels in the brains of 27 chronic TBI patients and 14 healthy subjects.

In addition to imaging, subjects underwent seven neuropsychological tests. Study participants were also assessed for post-concussive symptoms using the Brief Symptom Inventory-Somatic and Rivermead Post-Concussion Questionnaire, which evaluates severity of cognitive and emotional symptoms such as headaches and depression.

The findings revealed differences in multiple regions of the brain, which could mean new opportunities for tailored TBI therapies. The results showed deficits in cerebrovascular reactivity with TBI patients. While vascular reactivity is decreased in chronic TBI, the study showed that increased cerebrovascular reactivity in subcortical regions of the brain (hippocampus, amygdala, thalamus, caudate, putamen) is associated with more post-concussive symptoms.

"These findings underscore the importance for precise diagnosis with TBIs, to ensure the right therapies are identified for patients," Diaz-Arrastia said. "By nature, TBI injuries always vary—the brain damage is not the same in any two patients. If we have a therapy that could target the specific lesion that’s unique for each patient, then we can treat patients with better, more appropriate therapies. Overall, our vision for the future is that patients with TBI, and perhaps even other disorders, can have their microvascular function assessed as part of a routine neurological evaluation to help find the right treatment for each patient."

The study was sponsored by the U.S. Department of Defense, through the Center for Neurosciences and Regenerative Medicine and the Military Clinical Neuroscience Center of Excellence. View the full abstract on the AAN website.

Editor’s Note: Diaz-Arrastia was previously employed by the U.S. Department of Defense, along with co-authors Woodson and Dr. Kimbra Kenney.



Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.